This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Arilvax

GlaxoSmithKline plc

Drug Names(s): Yellow fever vaccine, YF-VAX

Description: Arilvax is a yellow fever vaccine that contains a live, weakened form of the yellow fever virus. It provokes the body's immune response to provide immunity against yellow fever without causing the disease.

Deal Structure: In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acquisition was completed in September 2008.

GlaxoSmithKline and Novartis
In April 2014, GSK and Novartis entered into a sale agreement under which GSK has agreed to sell, upon completion of the Transaction, the rights to GSKs currently marketed oncology portfolio, related R&D activities and its AKT inhibitor currently in development as well as to grant Novartis preferred partner rights for future commercialisation of GSK oncology products for an aggregate cash consideration of $16 billion. Up to $1.5 billion of this cash consideration depends on the results of the COMBI-d trial, a Phase III study evaluating the safety and efficacy of the combination of Tafinlar (BRAF) and Mekinist (MEK) versus BRAF monotherapy in patients with unresectable or metastatic...See full deal structure in Biomedtracker

Partners: Sanofi


Arilvax News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug